Results 71 to 80 of about 8,795,233 (257)
Advanced Science, EarlyView.Boiling Histrotripsy (BH), a mechanical form of focused ultrasound (FUS), allows for non‐invasive and non‐ionizing tissue destruction. Utilizing a BH treatment protocol that yielded bifurcating primary tumor growth responses, we found that immediate BH‐induced tumor growth control identifies tumors with acute reductions in antigen‐presenting cells (APC)
Lydia E. Kitelinger +8 more
wiley +1 more source
Phase II trial of preoperative radiochemotherapy with concurrent bevacizumab, capecitabine and oxaliplatin in patients with locally advanced rectal cancer [PDF]
, 2013 Background: Preoperative radiochemotherapy (RCT) with 5-FU or capecitabine is the standard of care for patients with locally advanced rectal cancer (LARC). Preoperative RCT achieves pathological complete response rates (pCR) of 10-15%.
Erik Engel +19 more
core +1 more source
Post-Neoadjuvant Treatment Strategies in Breast Cancer
, 2022 Neoadjuvant chemotherapy enables close monitoring of tumor response in patients with breast cancer. Being able to assess tumor response during treatment provides an opportunity to evaluate new therapeutic strategies.
Bálint Tamaskovics +12 more
core +1 more source
Advanced Science, EarlyView.Model illustrating the proposed mechanism by which chemotherapy‐induced downregulation of OGT disrupts SNAP29 O‐GlcNAcylation, promoting STX17‐SNAP29‐VAMP8 SNARE complex assembly and protective autophagy, leading to chemoresistance, which in turn establishes a feedforward loop to perpetuate drug tolerance.
Liang Tang +9 more
wiley +1 more source
Role of surgery in T4N0-3M0 esophageal cancer
World Journal of Surgical Oncology, 2023 Background This study aimed to investigate an unsettled issue that whether T4 esophageal cancer could benefit from surgery. Methods Patients with T4N0-3M0 esophageal cancer from 2004 to 2015 from the Surveillance, Epidemiology, and End Results (SEER ...
Chen Qi +6 more
doaj +1 more source
Background and objective: Multiple markers have been proposed, but there are no reliable pre-treatment markers that predict tumor response to total neoadjuvant therapy in patients with locally advanced rectal cancer.
Héctor Guadalajara +10 more
core +1 more source
Role for Neoadjuvant Systemic Therapy for Potentially Resectable Pancreatic Cancer
, 2023 Despite aggressive adjuvant management, a high percentage of patients who undergo appropriate surgical resection for pancreatic cancer will see their cancer recur and thus will not be cured. An important paradigm shift to achieve better outcomes has been
Brandon G. Smaglo
core +1 more source
Advanced Science, EarlyView.This study reveals that Tex10 drives oxaliplatin resistance in colorectal cancer by competitively binding BRD9 to disrupt the ncBAF complex, thereby suppressing AMBRA1 transcription and ULK1‐mediated autophagy. Gemcitabine is identified as a direct Tex10 inhibitor that restores autophagy and overcomes resistance.
Ping Xu +9 more
wiley +1 more source
Total Neoadjuvant Therapy in Localized Pancreatic Cancer: Is More Better?
Pancreatic ductal adenocarcinoma (PDAC) poses a significant challenge in oncology due to its advanced stage upon diagnosis and limited treatment options.
Benjelloun El Ghali +4 more
core +1 more source
Advanced Science, EarlyView.VEGFR‐2 signaling in OSCC activates Src–STAT6‐dependent CSF2 transcription, driving tumor‐derived GM‐CSF secretion. GM‐CSF programs neutrophils to express PD‐L1 through STAT5–mTOR/S6K signaling, suppressing cytotoxic CD8+ T cells. This pathway reveals a tumor–neutrophil immune checkpoint circuit that limits anti‐PD‐1 responsiveness in OSCC.
Fangxing Zhu +13 more
wiley +1 more source